449756-95-0

Usage

Uses

Used in Pharmaceutical Industry:
(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)METHANAMINE is used as a potential active pharmaceutical ingredient for the development of new drugs. Its unique structure and potential pharmacological activities make it a promising candidate for the treatment of various diseases and conditions.
Used in Medicinal Chemistry Research:
(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)METHANAMINE is used as a research compound in medicinal chemistry. It helps scientists understand its properties, interactions with biological systems, and potential applications in drug development.

Upstream product

• 449758-28-5 5-chloro-2-(1H-tetrazol-1-yl)benzonitrile 
• 449758-27-4 5-chloro-2-(1H-tetrazol-1-yl)benzamide 
• 449758-26-3 5-chloro-2-(1H-tetrazol-1-yl)benzoic acid 
• 635-21-2 5-chloroanthranilic acid 
• 1201687-15-1 tert-butyl 5-chloro-2-(1H-tetrazol-1-yl)benzylcarbamate 

Downstream Products

• 924901-49-5 2-(5-chloro-2-tetrazol-1-yl-benzylcarbamoyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 681128-16-5 1-(tert-butoxycarbonyl)-N-[5-chloro-2-(1H-tetrazol-1-yl)benzyl]-4,4-difluoro-L-prolinamide 
• 1201686-45-4 (5S)-N-[5-chloro-2-(1H-tetrazol-1-yl)benzyl]-1-[(2R)-2-(4-fluorophenyl)-2-hydroxyacetyl]-4,5-dihydro-1H-pyrazole-5-carboxamide 
• 450415-35-7 2-{6-chloro-3-[2,2-difluoro-2-(1-oxy-pyridin-2-yl)-ethylamino]-2-oxo-2H-pyrazin-1-yl}-N-(5-chloro-2-tetrazol-1-yl-benzyl)-acetamide 
• 1201687-01-5 (3S)-N-[5-chloro-2-(1H-tetrazol-1-yl)benzyl]-2-[(2R)-2-hydroxy-3,3-dimethylbutanoyl]pyrazolidine-3-carboxamide 
• 1097133-53-3 (1S,3S,5S)-2-[(R)-2-(3-chlorophenyl)-2-hydroxyacetyl]-2-azabicyclo[3.1.0]hexane-3-carboxylic acid 5-chloro-2-tetrazol-1-ylbenzylamide 
• 1097134-10-5 (1S,3S,5S)-N-[[5-chloro-2-(tetrazol-1-yl)phenyl]methyl]-4-[(2R)-2-hydroxy-3-pyrazol-1-ylpropanoyl]-4-azabicyclo[3.1.0]hexane-3-carboxamide 
• 1097134-11-6 (1R,4S,5S)-N-[[5-chloro-2-(tetrazol-1-yl)phenyl]methyl]-3-[(2R)-2-hydroxy-3-pyrazol-1-ylpropanoyl]-3-azabicyclo[3.1.0]hexane-4-carboxamide 
• 1097133-50-0 (1S,3S,5S)-2-((R)-2-hydroxy-3-pyridin-2-ylpropionyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid 5-chloro-2-tetrazol-1-ylbenzylamide 
• 1097133-46-4 (1R,3S,5R)-2-[(R)-2-hydroxy-3-(1-methylcyclopropyl)propionyl]-2-azabicyclo[3.1.0]hexane-3-carboxylic acid 5-chloro-2-tetrazol-1-ylbenzylamide 
• 1097133-43-1 (1R,2S,5S)-3-[(R)-2-hydroxy-3-(1-methylcyclopropyl)propionyl]-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 5-chloro-2-tetrazol-1-ylbenzylamide 

Relevant academic research and scientific papers

PLASMA KALLIKREIN INHIBITORS AND USES THEREOF

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

Benzimidazole derivative and pharmaceutical purposes thereof

The invention discloses a benzimidazole derivative and pharmaceutical purposes thereof, and particularly discloses a benzimidazole derivative shown in a formula I and purposes of the benzimidazole derivative to preparation of drugs for treating and/or pre

A one-pot asymmetric synthesis of a N-acylated 4,5-dihydropyrazole, a key intermediate of thrombin inhibitor AZD8165

A short, chromatography-free, and scalable synthetic route to thrombin inhibitor 1, the active metabolite of the propionic ester prodrug AZD8165, has been developed. The key synthetic step involved cycloaddition of TMS-diazomethane and ethyl acrylate to give an intermediate racemic dihydropyrazole which was reacted with enantiomerically pure 4-fluoro mandelic acid chloride in a one-pot dynamic kinetic resolution (DKR) process.

Novel Compounds 148

This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containi

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: wherein R1 is, for example, hydrogen, Cl, or cyano, and R2 is, for example, hydrogen,

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and treating blood coagulation and cardiovascular disorders and have the following structure: wherein R3 is hydrogen or halogen, and u is N or CH.